<DOC>
	<DOCNO>NCT02382276</DOCNO>
	<brief_summary>The long-term safety efficacy nalmefene hydrochloride 20 mg patient alcohol dependence evaluate multicenter , open-label , uncontrolled trial .</brief_summary>
	<brief_title>A Long-term Extension Study Phase 3 Study Nalmefene ( 339-14-001 ) Patients With Alcohol Dependence</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Nalmefene</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Patients complete Study 33914001 Patients sign informed consent form Study 33914002 The patient clinically significant unstable illness ( eg , complication New York Heart Association ( NYHA ) class III IV heart failure angina pectoris , renal function disorder estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73 m2 , hepatic failure , neoplastic disorder ) The patient clinically significant abnormal electrocardiogram ( ECG ) inappropriate participation trial opinion investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>